Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    22991696 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis
Condition: Conjunctivitis, Allergic
Interventions: Drug: Bepreve;   Drug: Placebo;   Drug: Bepotastine Besilate
2 Completed
Has Results
Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis
Condition: Allergic Conjunctivitis
Interventions: Drug: Bepreve (bepotastine besilate ophthalmic solution) 1.5%;   Drug: placebo comparator;   Drug: Bepotastine Besilate Ophthalmic Solution 1.0%

Indicates status has not been verified in more than two years